TTY Biopharm


Concise Prescribing Info
Doxorubicin HCl
Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm3) & extensive mucocutaneous or visceral disease. 1st-line systemic chemotherapy or 2nd-line chemotherapy in AIDS-KS patients w/ disease progression or in patients intolerant to, prior combination systemic chemotherapy comprising of at least 2 of the following: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). In combination w/ bortezomib for progressive multiple myeloma in patients who have received at least 1 prior therapy & who have already undergone or unsuitable for bone marrow transplant.
Dosage/Direction for Use
Breast/ovarian cancer 50 mg/m2 IV once every 4 wk as long as the disease does not progress & patient continues to tolerate treatment. AIDS-KS patient 20 mg/m2 IV every 2-3 wk for 2-3 mth. Multiple myeloma 30 mg/m2 on day 4 of bortezomib 3-wk regimen as 1 hr infusion immediately after bortezomib infusion. Bortezomib regimen: 1.3 mg/m2 on days 1, 4, 8 & 11 every 3 wk.
History of hypersensitivity. Not to be used in patients w/ AIDS-KS who are on local therapy or systemic α-interferon. Lactation.
Special Precautions
Discontinue use if infusion-associated ARs occur. Impaired cardiac function; CHF due to cardiomyopathy; patients who have received other anthracyclines; persistent severe myelosuppression; diabetic patients. Not recommended in AIDS-KS patients w/ splenectomy. May affect ability to drive & operate machines. Not recommended during pregnancy. Not recommended in childn <18 yr.
Adverse Reactions
Palmar-plantar erythrodysesthesia, stomatitis/mucositis & nausea; infusion-associated reaction; myelosuppression associated w/ anaemia, thrombocytopaenia, leukopaenia.
Drug Interactions
Potentiated toxicity of other anti-cancer therapies. Exacerbated cyclophosphamide-induced hemorrhagic cystitits & enhanced hepatotoxicity of 6-mercaptopurine. Induced bone marrow suppression w/ other cytotoxic agents.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Lipo-Dox infusion conc 2 mg/mL
10 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in